Swiss Market Entry Brief for Health Companies

General information only, not legal, regulatory or medical advice. Please read the legal notice at the end before relying on this brief.

Executive summary

Switzerland is one of the world's most valuable health markets, and since 2021 it has been a separate regulatory market from the EU for medical devices and in vitro diagnostics. A CE mark is still the starting point, but it no longer opens the Swiss door on its own.

For an international health company, entering Switzerland comes down to four things:

1. A Swiss legal presence. Foreign manufacturers of medical devices and IVDs need a Swiss authorised representative (CH-REP), and every product placed on the market needs a Swiss importer.
2. Registration. Economic operators and devices must be registered with Swissmedic, increasingly through its swissdamed database.
3. Swiss-ready product information. Labelling and instructions in the national languages your users speak, and advertising that follows Swiss rules.
4. A channel plan. Pharmacies, drugstores, wholesalers, retail, online marketplaces, direct-to-consumer and hospitals each work differently, and the order in which you open them decides your economics.

None of this is hard for a company that plans it. It becomes expensive for one that discovers it after shipping. This brief shows what to plan, in what order, and where foreign brands most often stumble.

Why Switzerland

Swiss households spend among the most on health per person in the world, pay a large share out of their own pocket, and trust their pharmacists. For a health brand, that combination means a market that rewards quality and is willing to pay for it.

Two features matter most for consumer health. Pharmacy density is low by European standards, about 20 per 100,000 inhabitants against a European average of about 31, so each pharmacy carries more weight. And with a fifth of costs paid out of pocket, consumers are used to buying health products themselves.

Switzerland is not the EU

Since the EU–Swiss mutual recognition agreement stopped covering medical devices (26 May 2021) and IVDs (26 May 2022), Switzerland applies EU-equivalent product rules but treats every foreign manufacturer as a third-country manufacturer, including those based in the EU. An updated agreement was signed on 2 March 2026, but it still needs ratification by both sides and, in Switzerland, most likely a public vote. Until then, the current framework remains unchanged.

In practice, four Swiss requirements sit on top of your CE mark:

The CH-REP's address must appear on the label of MDR devices and IVD self-tests; for other IVDs it may sit in an accompanying document. Full details are in Swissmedic's information sheet on economic operators.

Dates to plan around

Source: Swissmedic information sheet on economic operators.

Your pathway by product type

The first question is not "how do we sell?" but "what is our product in Swiss law?". Classification decides the regulator, the paperwork, who may sell it and what you may say about it.

Two points surprise most companies. First, being EU-based changes nothing: an EU manufacturer needs a CH-REP just like a US or UK one. Second, a product that sits on the border between categories, such as a supplement with a health message or a device with a medicinal ingredient, should be classified before anything is printed. Getting it wrong means relabelling, or worse, withdrawing stock.

Routes to market

The right first channel depends on your product, your price point and how much explanation it needs. Most successful entries open one or two channels well, prove sell-through, then expand.

Reimbursement in one paragraph. Mandatory basic health insurance covers medicines on the Specialities List (SL), laboratory analyses on the Analysis List, and devices on the MiGeL list. Most consumer self-tests, supplements and wellness products are paid out of pocket. That is not a weakness: it means no reimbursement dossier, faster entry and pricing set by the market rather than by a tariff.

One economic warning. Single low-priced items shipped individually across Switzerland rarely pay for themselves. The model that fixes this depends on your category and price point, and it is one of the first things we work out in a personalised brief.

Labelling, languages, advertising and pricing

The rules that most often hold up a launch are not the big regulatory ones, but the details on the box and in the marketing.

• Three languages on the pack. Devices and IVDs for lay users need product information in German, French and Italian (Art. 16 MedDO, Art. 15 IvDO). Many EU multilingual packs already include all three; check before you print a Swiss version.
• The right names on the label. Manufacturer always; the CH-REP on MDR devices and IVD self-tests; the Swiss importer on the device, packaging or an accompanying document.
• Repackaging and translation are possible, but regulated. An importer may translate or repackage under conditions, but relabelled devices must be notified to Swissmedic first (Swissmedic).
• Advertising must match the label. Claims may only contain statements that correspond to the product information; misleading claims on purpose, safety or performance are prohibited; professional-use devices may not be advertised to the public (Art. 69 MedDO). Your website, social posts and retailer pages all count.
• Supplement claims come from a list. Health claims on food supplements must be on the approved list or individually approved; disease claims turn a supplement into an unauthorised medicine.
• Price for Switzerland, not as a conversion. Swiss consumers expect Swiss prices in CHF, and channel margins for wholesalers and pharmacies have to fit inside them. Set the shelf price first, then work backwards.

In Switzerland, "Swissmedic-approved" is a red flag, not a selling point: Swissmedic does not approve medical devices. Say "CE-marked and registered in Switzerland" instead.

The entry path

Every Swiss entry follows the same five stages. Timing depends on the product class and on how ready your documentation is, so we agree it per product after the first stage.

1. Assess. Classify each product under Swiss law, check its certificates and technical file, and test channel fit and price points.
2. Register. Appoint the CH-REP, set up the importer, obtain the CHRN registrations and register devices in swissdamed.
3. Place. Prepare Swiss labelling, agree wholesale and logistics, and list with the first channels.
4. Launch. Localise the story for German-, French- and Italian-speaking Switzerland and run launch communication within the advertising rules.
5. Scale. Plan demand, add channels and products, and keep vigilance and registrations current.

Readiness checklist. If you can tick these, you are ready for a first conversation:

• We know how each product is classified (device class, IVD class, supplement, medicine).
• Our CE certificates or declarations of conformity are current, and we can share the technical documentation within 7 days.
• Our packaging carries, or can carry, German, French and Italian product information.
• We know whether our products are for lay users, professionals or both.
• We have a target shelf price in CHF and know our margin structure.
• We know which channel we want first, and why.

Seven mistakes foreign health brands make

1. Assuming the CE mark is enough. Since 2021 for devices and 2022 for IVDs, it is not. EU companies are treated as foreign manufacturers too.
2. Shipping before the importer is clear. Whoever receives the goods in Switzerland becomes the importer, with legal duties. A retailer or pharmacy importing directly takes on that role, often without knowing it.
3. Printing German-only packs. Switzerland is not a German-speaking market with extras. Romandie and Ticino buy too, and lay-use devices need all three languages.
4. Forgetting swissdamed. Device registration is mandatory from 1 July 2026, and from 2027 your Swiss partners must check it before they sell.
5. Borrowing claims from other markets. A claim that works in the UK or US can be misleading under Swiss rules, or turn a supplement into an unauthorised medicine.
6. Opening every channel at once. Pharmacies, marketplaces and your own webshop compete on price if launched together. Sequence them.
7. Treating Switzerland as an afterthought of the DACH plan. Swiss buyers, pricing and media are their own. A Swiss launch run from Germany usually shows.

Your personalised Swiss Market Entry Brief

This brief describes Switzerland for every health company. Yours should describe Switzerland for your products. 11Alto prepares a personalised Swiss Market Entry Brief for each company that asks: a clear, decision-ready plan built on your portfolio, your documentation and your commercial goals.

What it covers

It is prepared by 11Alto with our specialists in regulatory affairs, logistics, market access and communications, and delivered as a working document you can take to your board. The fee is fixed and agreed up front, and is credited in full if you go on to work with us.

Request yours: write to info@11alto.com with your company name, product categories and target timing, or use the contact form.

About 11Alto

11Alto is a Zürich-based market-entry platform for international health companies. We represent, distribute and operate health brands in Switzerland, with one contract and one accountable lead.

11Alto AG · Schifflände 26, 8001 Zürich · CHE-257.572.890 · info@11alto.com

Legal notice

General information only. This brief is published by 11Alto AG for general information. It reflects 11Alto AG's reading of publicly available sources as of November 2026 and is not updated automatically. It is not legal, regulatory, medical, tax or other professional advice, and it does not replace an assessment of your specific product by a qualified adviser or the competent authority.

No advisory relationship. Reading or sharing this brief does not create a client, advisory or contractual relationship with 11Alto AG. Any service, including the personalised brief, is provided only under a separate written agreement, whose terms then apply.

No warranty, limited liability. 11Alto AG has prepared this brief with care but gives no warranty, express or implied, that it is complete, accurate or current. To the fullest extent permitted by law, 11Alto AG and its directors, employees and partners accept no liability for any direct or indirect loss arising from the use of, or reliance on, this brief.

Check before acting. Laws, regulations, fees, deadlines and authority practice change, and how they apply depends on each product and case. Confirm the current requirements with the competent authority, such as Swissmedic or the Federal Food Safety and Veterinary Office (FSVO), before taking any decision. Only legal texts published in the official compilation of federal law (fedlex.admin.ch) are binding.

Third parties. Third-party figures, names and trademarks are cited from their public sources and remain the property of their owners; their mention does not imply endorsement or partnership. 11Alto AG is not responsible for the content of linked websites.

Applicable law. This notice is governed by Swiss law. The place of jurisdiction is Zürich, Switzerland.

Sources

• FSO health cost figures 2024, reported by ZWP online (27 April 2026)
• pharmaSuisse, Facts & Figures 2025
• KMU Portal: Switzerland remains the world's most innovative country (WIPO GII 2025)
• scienceindustries: foreign trade 2025
• KMU Portal: Swiss Biotech Report 2026
• Swissmedic: new active substances and indication extensions 2025
• Swissmedic: information sheet on obligations of economic operators
• Swissmedic: deadline for product registration in swissdamed
• MedTech Europe: EU–Switzerland relations, 5 March 2026
• MedDO Art. 16 (languages) and Art. 69 (advertising)
• IvDO Art. 15 (product information) and Art. 61 (supply to the public)
• FSVO: food supplements
• TPA Art. 10 (marketing authorisation conditions) and Swissmedic FAQ on Art. 13 TPA
• Galenica corporate information